BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, BioCryst Pharmaceuticals, Inc. keeps $36 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 10 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
BioCryst Pharmaceuticals’ revenue topped consensus in the second fiscal quarter of 2026, with results reported August 5, 2026, as revenue rose 33.6% to about $218.2 million, up from $163.4 million a year ago. On the consensus yardstick, revenue of $218.2 million topped the $183.3 million estimate (+19.1%), pointing to a materially higher quarter than analysts were modeling. Profitability was high on a margin basis, with gross margin at roughly 98% and operating margin around 45%, alongside operating income of about $98.5 million; gross profit came in at roughly $214.4 million. The company also generated operating cash flow of about $104.3 million during the quarter. For the next period, consensus calls for EPS of $0.10 on revenue of $165.4 million.
Next report — what to expect
BioCryst Pharmaceuticals, Inc. (BCRX) reports on November 2, 2026. Wall Street expects EPS of $0.10 on revenue of $165.7 million. For trailing context, revenue grew +33.6% year over year last quarter. BioCryst has beaten EPS in 3 of its 8 most recent quarters, so focus on any variance versus these consensus targets.
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. develops and commercializes biotechnology medicines for rare and infectious diseases, with $874.8 million in revenue in FY2025. The NASDAQ-listed BCRX company centers on small-molecule therapeutics, particularly orally administered drug candidates, and sells approved products for hereditary angioedema and influenza.
Today's Snapshot
The day ended with BCRX 1.7% lower at 7.65, in line with a weaker sector. Trading was lighter than usual, with volume about half of its usual level.
Trading Volume
Below 10d avg (5.2M)
2.7M
vs S&P 500 Today
Underperforming Market
-1.15%
Updated: October 23, 2026 at 20:27 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$7.92 - $8.79Sell
- RSI (14)35.87Neutral
- Stochastic %K (14, 3, 3)9.03Buy
- MACD Level (12, 26)-0.27Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.